Skip to main content

Neoadjuvant Nivolumab, Ipilimumab Safe for dMMR Colon Cancer

Medically reviewed by Carmen Pope, BPharm. Last updated on June 6, 2024.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, June 5, 2024 -- Neoadjuvant nivolumab plus ipilimumab has an acceptable safety profile in patients with locally advanced mismatch repair-deficient (dMMR) colon cancer, according to a study published in the June 6 issue of the New England Journal of Medicine.

Myriam Chalabi, M.D., Ph.D., from the Netherlands Cancer Institute in Amsterdam, and colleagues conducted a phase 2 study involving patients with nonmetastatic, locally advanced, previously untreated dMMR colon cancer treated with neoadjuvant nivolumab plus ipilimumab. Safety, defined by timely surgery, and three-year disease-free survival were the two primary end points.

The researchers found that 113 of the 115 enrolled patients underwent timely surgery; two had surgery delayed by more than two weeks. In five patients (4 percent), grade 3 or 4 immune-related adverse events occurred; no patients discontinued treatment due to adverse events. A pathological response occurred in 98 percent of the 111 patients included in the efficacy analysis, including 95 and 68 percent with a major pathological response and a pathological complete response, respectively (defined as ≤10 and 0 percent residual viable tumor). No patients had disease recurrence during a median follow-up of 26 months.

"The high proportion of patients with a pathological response observed after only four weeks of treatment in our study, together with the safety profile, may provide sufficient justification to provide immunotherapy to patients with radiographically assessed high-risk disease, especially if three-year disease-free survival data from this study are positive," the authors write.

The study was funded by Bristol Myers Squibb, the manufacturer of nivolumab and ipilimumab.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

FIT Screening Cuts Risk of Death From Colorectal Cancer

TUESDAY, July 23, 2024 -- Screening with fecal immunochemical tests (FITs) lowers the risk of dying from colorectal cancer (CRC), according to a study published online July 19...

NCCN: Cancer Drug Shortages Remain a Challenge for Clinicians

FRIDAY, June 28, 2024 -- Almost 90 percent of medical centers report cancer drug shortages, which often impact clinical trials, according to the results of a National...

PIK3CA Could Guide Use of COX-2 Inhibitors in Treatment for Colon Cancer

THURSDAY, June 27, 2024 -- PIK3CA mutational status may be beneficial for predicting response to addition of the cyclooxygenase 2 (COX-2) inhibitor celecoxib to standard adjuvant...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.